Round Rock, TX, United States of America

Erin Willert

USPTO Granted Patents = 22 

 

 

Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 68(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
Loading Chart...
22 patents (USPTO):Explore Patents

Title: Innovations by Erin Willert: Pioneering Clinical Methods and Binding Proteins

Introduction

Erin Willert, based in Round Rock, TX, has made significant contributions to the field of biotechnology, particularly in the development of novel clinical methods and binding proteins that target specific cell types. With an impressive portfolio of 21 patents, Willert's work is making strides in the treatment of cancers and disorders involving specific cells.

Latest Patents

Among Willert's latest patents is a groundbreaking invention focused on clinical methods for using a PD-L1-binding molecule that comprises a Shiga toxin effector. This innovative disclosure details PD-L1-binding molecules that can selectively kill PD-L1 positive tumor cells, making it an essential therapeutic approach for treating various types of cancers, including non-small cell lung cancer. Additionally, Willert has developed CD38-binding proteins that possess a CD38-binding region for targeted delivery and a Shiga toxin A Subunit effector polypeptide. These proteins show promise for selectively eliminating CD38-expressing cells, especially in cancers like multiple myeloma, highlighting their potential impact in oncology.

Career Highlights

Willert has worked with notable companies in the pharmaceutical and biotechnology sectors, including Molecular Templates, Inc. and Millennium Pharmaceuticals Limited. Through these roles, he has been able to translate innovative research into practical therapeutic solutions, furthering advancements in medical technology.

Collaborations

Throughout his career, Willert has collaborated with esteemed colleagues, including Eric Poma and Jack Higgins. These collaborations have been vital in enhancing the development and application of his inventions, blending expertise and fostering innovation within the industry.

Conclusion

With a robust patent portfolio and a commitment to scientific advancement, Erin Willert continues to be a key figure in the biotechnology field. His innovative approaches to clinical methods and binding proteins not only demonstrate the potential for targeted cancer therapies but also reflect the spirit of innovation that drives the industry forward.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…